Yihan Industrial Co.,Ltd.

Specialize in anabolic steroids, body-building supplements and Steroid Hormone Raw Powder

Home
Products
About Us
Factory Tour
Quality Control
Contact Us
Request A Quote
Home ProductsPharmaceutical Intermediates

CAS 231277-92-2 Cancer Chronic Myeloid Leukemia Treatment Raw Material Lapatinib Ditosylate

Certification
Good quality Tren Anabolic Steroid for sales
Good quality Tren Anabolic Steroid for sales
As usual, you are on top of business with professionalism. Thank you for the prompt service. Look fwd to next.

—— Milton Rojas

The quality is sooo stable while order from your guys these years,it is amazing quality ,I will never change my source cos it bring me good feedback!!

—— Alex Clinton

I'm Online Chat Now

CAS 231277-92-2 Cancer Chronic Myeloid Leukemia Treatment Raw Material Lapatinib Ditosylate

China CAS 231277-92-2 Cancer Chronic Myeloid Leukemia Treatment Raw Material Lapatinib Ditosylate supplier
CAS 231277-92-2 Cancer Chronic Myeloid Leukemia Treatment Raw Material Lapatinib Ditosylate supplier CAS 231277-92-2 Cancer Chronic Myeloid Leukemia Treatment Raw Material Lapatinib Ditosylate supplier

Large Image :  CAS 231277-92-2 Cancer Chronic Myeloid Leukemia Treatment Raw Material Lapatinib Ditosylate

Product Details:

Place of Origin: China
Brand Name: YIHAN
Certification: GMP,USP,BP,ISO 9001
Model Number: 231277-92-2

Payment & Shipping Terms:

Minimum Order Quantity: 10G
Price: USD0.1-2 +g
Packaging Details: Discreet Package or as Required.
Delivery Time: 3-5 work days
Payment Terms: MoneyGram,Paypal, T/T, Western Union
Supply Ability: 5000kg/Month
Contact Now
Detailed Product Description
Product Name: Lapatinib Advantages: Reship Policy
Suitable For: Adult CAS: 231277-92-2
Type: Pharmaceutical Intermediate Appearance: White Powder
Grade: High Build And Good Leveling,Pharmaceutcial Grade

1. Basic Info

 

Product Name: Lapatinib
CAS Number: 231277-92-2
Molecular Weight: 581.058
Molecular Formula: C29H26ClFN4O4S
Specification: 99%
Appearance: White powder

 

 

2. Descriptions:

 

Lapatinib (INN), used in the form of lapatinib ditosylate, (USAN) (Tykerb/Tyverb, GSK) is an orally active drug for breast cancer and other solid tumours.[1] It is a dual tyrosine kinase inhibitor which interrupts the HER2/neu and epidermal growth factor receptor (EGFR) pathways.[2] It is used in combination therapy for HER2-positive breast cancer. It is used for the treatment of patients with advanced or metastatic breast cancer whose tumors overexpress HER2 (ErbB2).

 

3. detail

 

Description White powder Complies
Identification IR Complies
  HPLC Complies
Heavy metal ≤10ppm 5ppm
Pb ≤3ppm 1.5ppm
Hg ≤0.1ppm 0.05ppm
Cd ≤1ppm 0.2ppm
Loss on drying ≤0.5% 0.12
Residue on lgnition ≤0.1% 0.03
Single impurity ≤0.5% 0.12
Total impurity ≤1.0% 0.29
Total bacteria ≤1000cfu/g <1000
Yeast and Mould ≤100 cfu/g <000
E.coli/25g Absent Absent
Salmonella/25g Absent Absent
Assay ≥99.0% 0.994
Conclusion Conforms with USP/EP standards

 

 

4. Applications:

 

Lapatinib is a cancer medicine that interferes with the growth and spread of cancer cells in the body.

Lapatinib is used to treat a certain type of hormone-related breast cancer that has progressed or spread after treatment with other cancer medicines.

In postmenopausal women, lapatinib is given in combination with a hormonal medicine called letrozole (Femara). In others, lapatinib is given together with a cancer medicine called capecitabine (Xeloda).

 

On March 13, 2007, the U.S. Food and Drug Administration (FDA) approved lapatinib in combination therapy for breast cancer patients already using capecitabine (Xeloda, Roche). In January 2010, Tykerb received accelerated approval for the treatment of postmenopausal women with hormone receptor positive metastatic breast cancer that overexpresses the HER2 receptor and for whom hormonal therapy is indicated.

Pharmaceutical company GlaxoSmithKline (GSK) markets the drug under the propriety names Tykerb (mostly US) and Tyverb (mostly Europe). The drug currently has approval for sale and clinical use in the US, Australia, Bahrain, Kuwait, Venezuela, Brazil,New Zealand,South Korea, Switzerland, Japan, Jordan, the European Union, Lebanon, India and Pakistan.

On the 2nd of August 2013, India's Intellectual Property Appellate Board revoked the patent for Glaxo's Tykerb citing its derivative status, while upholding at the same time the original patent granted for Lapatinib.

The drug lapatinib ditosylate is classified as S/NM (a synthetic compound showing competitive inhibition of the natural product) that is naturally derived or inspired substrate (Gordon M. Cragg, Paul G. Grothaus, and David J. Newman, Impact of Natural Products on Developing New Anti-Cancer Agents, Chem. Rev. 2009, 109, 3012–3043)

 

other product : 

 

Product Name Cas No
Erlotinib hydrochloride 183319-69-9
Octenidine Dihydrochloride 70775-75-6
Lapatinib Ditosylate 388082-77-7
Gefitinib 184475-35-2
Dasatinib 302962-49-8
Crizotinib 877399-52-5
Ibrutinib 936563-96-1
BIBW2992 DiMaleate 850140-73-7
Cabozantinib Malate 1140909-48-3
lenvatinib Mesylate 857890-39-2
Ceritinib (LDK378) 1032900-25-6
Cabozantinib 849217-68-1
lenvatinib 417716-92-8
Imatinib mesylate 220127-57-1

 

About us:

we, Yihan Industrial Co., Ltd from china are specilized in steroids powder , semi-finished liquids , peptides , Sarm powder,HGH,HCG,Finished Liquid and other pharmaceutical materials for many years .

If you have any further questions or need a sample,Please do not hesitate to contact me.Thank you!

Juddy Email: sales01@yihanind.com
Phone(Whatsapp/ Wechat/Skype) +8613243765351
 

 

CAS 231277-92-2 Cancer Chronic Myeloid Leukemia Treatment Raw Material Lapatinib Ditosylate

 

 
 

Contact Details
Yihan Industrial Co.,Ltd.

Contact Person: Juddy Zhang

Tel: +8613243765351

Send your inquiry directly to us (0 / 3000)